eriodictyol has been researched along with Invasiveness, Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asao, Y; Matsuda, H; Miyagawa, K; Nakashima, S; Takayama, S; Xu, F; Yoshida, K; Yoshikawa, M | 1 |
| Du, Q; Li, L; Li, W; Liu, Q; Liu, S; Lv, F; Xi, X | 1 |
2 other study(ies) available for eriodictyol and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa.
Topics: Cell Differentiation; Cell Proliferation; Convolvulaceae; Enzyme Precursors; Fibrosarcoma; Flavonoids; Gelatinases; HL-60 Cells; Humans; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Plant Extracts; Rotenone; Tumor Cells, Cultured; U937 Cells | 2007 |
Eriodictyol inhibits glioblastoma migration and invasion by reversing EMT via downregulation of the P38 MAPK/GSK-3β/ZEB1 pathway.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Down-Regulation; Epithelial-Mesenchymal Transition; Flavanones; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Molecular Docking Simulation; Neoplasm Invasiveness; Wound Healing; Zinc Finger E-box-Binding Homeobox 1 | 2021 |